Despite better understanding of it’s molecular biology, non-small cell lung cancer (NSCLC) remains a challenging disease to treat. Unfortunately, treatment options are still very limited and prognosis for advanced disease is poor. Immune surveillance plays a crucial role in a host’s defence against tumour cells, and this is particular relevant for lung cancer due to it’s high somatic mutational load, which increases the chances for the immune system to recognize cancer cells as ‘non-self’. Novel immunotherapies are emerging as an effective treatment for this disease. In this review, we present the data on immune checkpoint inhibitors for NSCLC, describing their mechanism of action, data efficacy from recent clinical trials, and strategies to select patients more likely to benefit from these agents.

Immune checkpoint blockade: a new era for non-small cell lung cancer / Califano, Raffaele; Kerr, Keith; Morgan, Robert David; Lo Russo, Giuseppe; Garassino, Marina; Morgillo, Floriana; Rossi, Antonio. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 18:9(2016), p. 59. [10.1007/s11912-016-0544-7]

Immune checkpoint blockade: a new era for non-small cell lung cancer

Lo Russo, Giuseppe
;
Rossi, Antonio
2016

Abstract

Despite better understanding of it’s molecular biology, non-small cell lung cancer (NSCLC) remains a challenging disease to treat. Unfortunately, treatment options are still very limited and prognosis for advanced disease is poor. Immune surveillance plays a crucial role in a host’s defence against tumour cells, and this is particular relevant for lung cancer due to it’s high somatic mutational load, which increases the chances for the immune system to recognize cancer cells as ‘non-self’. Novel immunotherapies are emerging as an effective treatment for this disease. In this review, we present the data on immune checkpoint inhibitors for NSCLC, describing their mechanism of action, data efficacy from recent clinical trials, and strategies to select patients more likely to benefit from these agents.
2016
Atezolizumab; CTLA-4; Durvalumab; immune checkpoint; Nivolumab; non-small cell lung cancer; PD-1; PD-L1; Pembrolizumab; antibodies; monoclonal; antibodies monoclonal, humanized; carcinoma; non-small-cell lung; cell cycle checkpoints; humans; prognosis; immunotherapy; oncology
01 Pubblicazione su rivista::01a Articolo in rivista
Immune checkpoint blockade: a new era for non-small cell lung cancer / Califano, Raffaele; Kerr, Keith; Morgan, Robert David; Lo Russo, Giuseppe; Garassino, Marina; Morgillo, Floriana; Rossi, Antonio. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 18:9(2016), p. 59. [10.1007/s11912-016-0544-7]
File allegati a questo prodotto
File Dimensione Formato  
Rossi_Immune-checkpoint-blockade.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 316.55 kB
Formato Adobe PDF
316.55 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1018479
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 35
social impact